Aug 5, 2021 Bayer has entered into an agreement to acquire Vividion Therapeutics in a $1,500,000,000 deal.

Bayer based at Leverkusen, Nordrhein-Westfalen, Germany.
“We exist to help people thrive – Advancing health and nutrition is what we do best and care about most.”

Acquirer’s Website: www.bayer.com/

Vividion Therapeutics based at San Diego, California, United States. “Vividion Therapeutics is a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for cancers and immune disorders. We believe our novel, industrial scale chemoproteomic platform provides us with an opportunity to remove boundaries of druggability and develop therapies for patients with critical unmet medical needs across multiple therapeutic areas.”

Acquiree’s Website: www.vividion.com/